BACKGROUND AND OBJECTIVE The BRAF(T1799A) mutation is reported to be associated to aggressive, persistent, and recurrent tumor in papillary thyroid carcinoma (PTC) patients. Association of the BRAF(T1799A) mutation in the primary tumor with the clinicopathological characteristics of PTC patients was analyzed. PATIENTS, MATERIAL AND METHODS Ninety-seven PTC patients were followed up for a medi...

PURPOSE Papillary thyroid carcinoma (PTC), the most common thyroid malignancy, usually possesses BRAF mutation or rearranged in translation (RET)/PTC rearrangements. PTC usually possesses BRAF mutation or RET/PTC rearrangements. The mutation status of patients with recurrent PTC has never been characterized in a large population. EXPERIMENTAL DESIGN Mutation status was determined in a cohort ...

BACKGROUND We evaluated the usefulness of follow-up BRAF(V600E) mutation analysis using ultrasonography-guided fine-needle aspiration (US-FNA) in diagnosis of thyroid nodules showing negative BRAFV600E mutation on prior analysis. METHODOLOGY/PRINCIPAL FINDING A total of 49 patients (men: 6, women: 43, mean age: 50.4 years) with 49 thyroid nodules were included. Patients had undergone initial ...

Serrated pathway colorectal cancers (CRCs) are characterised by a BRAF mutation and half display microsatellite instability (MSI). The Wnt pathway is commonly upregulated in conventional CRC through APC mutation. By contrast, serrated cancers do not mutate APC. We investigated mutation of the ubiquitin ligases RNF43 and ZNRF3 as alternate mechanism of altering the Wnt signal in serrated colorec...

The outcomes of patients with metastatic melanoma (MM) have significantly improved after the introduction BRAF-specific inhibitors. Herein is reported a patient MM and non-V600-BRAF mutation who responded to iBRAF/iMEK therapy. In July 2014, 63-year-old man presented 4.1mm-thick V600E-BRAF wild type on back. Metastases were identified in one sentinel node two 11 subsequently excised lymph nodes...

BACKGROUND Trophoblast antigen 2 (TROP2) is a human trophoblast cell-surface glycoprotein that is overexpressed in several types of epithelial cancers, and is suggested to be associated with an unfavorable prognosis. BRAF mutations are the most common genetic alteration in papillary thyroid carcinoma (PTC). We evaluated the correlation between TROP2 expression and BRAF mutation in PTC. METHOD...

OBJECTIVES Targeted therapies in non-small cell lung cancer (NSCLC) now also include inhibitors against mutated BRAF. We present clinicopathological characteristics of nearly one thousand unselected NSCLC patients tested for the targetable V600E/K BRAF-mutation. MATERIAL AND METHODS NSCLC routinely tested for EGFR-mutations at Oslo University Hospital in the period February 2011-July 2013 wer...

BRAF mutation is one of the important driver oncogene in non-small-cell lung cancer (NSCLC). Data on Chinese patients with BRAF-mutant NSCLC are inadequate. Hence, we conducted this study to investigate the clinicopathologic features and outcomes of Chinese patients with NSCLC and BRAF mutations. We identified patients with BRAF-mutant NSCLC between January 2012 and April 2016. Patient characte...

BACKGROUND The cobas 4800 BRAF V600 Mutation Test is a CE-marked and FDA-approved in vitro diagnostic assay used to select patients with metastatic melanoma for treatment with the selective BRAF inhibitor vemurafenib. We describe the pre-approval validation of this test in two external laboratories. METHODS Melanoma specimens were tested for BRAF V600 mutations at two laboratories with the: c...

After appropriate pathologic confirmation of the diagnosis of melanoma of every sample, tumor samples were tested for BRAF V600E using a kit based on the PCR/hybridization method. DNA extraction was performed using the QIAamp DNA FFPE Tissue kit (Qiagen) following the manufacturer’s instructions. The BRAF mutation was detected using the ViennaLab BRAF StripAssay® kit (ViennaLab Diagnostics GmbH...